NorthWest Biotherapeutics Inc (NWBO)

[IkeEsq]

For Al4door and JRIII, a response to JR’s stickied nonsense. That this drivel is stickied at all is a joke. Being fair and balanced is fine if you are presenting arguments from both sides that are supported by actual evidence. However, JRIII provides no evidence anywhere in his post.

You seem to be suggesting that just because the company isn't bankrupt she's done a good job. I disagree. Technically it is bankrupt,

No. Bankruptcy is a legal process a company or individual goes through which must be approved by a court. NWBO has not filed for bankruptcy. NWBO is not technically bankrupt, nor is there any evidence to suggest that it has even begun the process for filing for bankruptcy.

and her management has been a disaster of epic proportions. The evidence overwhelmingly supports my point of view, while your point of view depends entirely on a confluence of highly unlikely occurrences.

A conclusory statement without any evidentiary support. If there is overwhelming evidence, then why can it not be posted? Argument invalid.

They blew the trial and they know it, and now they are trying to cover their mess by manufacturing some backdoor approval that is a total shot in the dark. That's what all the evidence is pointing to, and though you try to pretend otherwise you know it, too.

Another conclusory statement without any evidence to support it. In fact, the evidence presented in the published article suggests that DC-VAX works and does not have serious side-effects. More to the point, Linda did not design the trial so if the trial itself fails, it could hardly be her fault.

The stock has free-fallen from $12 to penny status, destroying all shareholder value while the insiders have gotten rich. Do you deny that? Are you OK with that?

Although I am not an expert in this, I am under the impression that this is not an uncommon state of things with small bio-tech startups. The evidence suggests that the stock was manipulated by short sellers. See Smith on Stocks and Washington Post articles or this article on how manipulation is done. Nor is there any explanation for how they could possibly have prevented this from happening or how they were complicit in causing it. Also, there is still shareholder value as long as the stock is trading.

You have stated that the stock price is irrelevant until they unblind, which is just incomprehensible to me. How can it be irrelevant?

No, I said that the stock price is largely irrelevant [from now] until unblinding. It is relevant to financing but for the most part, it is likely to continue to trade somewhere in the .20s until unblinding. It is unlikely to go much lower because there are a lot of people who seem willing to buy when it drops lower and who feel that the trial will be a success. It is unlikely to go much higher because shorts can manipulate any rally for their own advantage. Until a larger pool of investors becomes interested, the stock is not likely to go anywhere. Whether it is at $0.27 or $0.22 is largely irrelevant.

If it had held even half of its peak value imagine where it would be if all of your unlikely occurrences were to occur. But no, we are at 23 cents and sinking fast, so where will it be if all of your unlikely occurrences were to occur now? The stock price is not irrelevant – ever!

But it didn’t and as I explained earlier, maintaining that price was never likely to happen. This is a company with no approved products, no revenue, and when it was at $6 a long path ahead to approval. There is no way it can maintain that kind of price when there are lots of people out there who can make a LOT of money manipulating it. The value of this company upon approval is not going to be based on its stock price now. That is why the current price is largely irrelevant. The price after approval is going to be based on the potential market for their products. Also, the price is not sinking fast. Your post from 2 weeks ago at $.23 and now it is selling at $0.223. Not exactly sinking fast.

It is the only reason we are here, as investors. Maybe you are here for a different reason, being a doctor and all, but if that is the case then why are you posting on a board for investors?

What makes you think that is the only reason all of us investors are here? I am certainly not here in the hopes that the interim pre-unblinding price goes up or down a few cents. I could not possibly care less about that. I am here because of where I believe that price will be after unblinding and approval. Other people may be here at least in part because they want to support a company that can help people with the most dire cancer to live longer.

Here is the most important question: Why haven't they unblinded the trial? Why is this trial still going more than two years past primary endpoint?

Sentiment_stocks already addressed this here so I won’t bother. The real question is why you think that you, with no knowledge in the field and little information about the study, have a better idea about when to conclude the study than do a group of doctors who practice in this field and have been getting all available data for the last 10 years? My personal take is that this company is likely to live or die as a result of this Phase III trial and they want to be sure that they have what they need to get approval. If they need to wait an extra 6-12 months to get from 85% to 95% or whatever, then that is what they will do.

And that question leads to this one: Why are they doing a spring refresh if they are going to unblind right after? Why not just unblind? What's the point of a spring refresh and the expense that goes with it when they could just stop the trial and take the blinders off?

They have discussed this, multiple times. The Spring Refresh provides them with data on how the trial is going. Specifically, it is showing them the existence and properties of the long tail. They NEVER committed to unblinding after the refresh, quite to the contrary, in fact. Once they stop the trial and take the blinders off they can’t restart if they determine that they do not have the data they need to get approval. I am far more concerned about them ending the trial before they secure the data needed for approval than I am with the possibility that they allow it to run a bit longer. Imagine the uproar if they stop the trial prematurely after 10 years and fail to get approval that they could have secured if they had waited a few more months.

If they are waiting for 36 months past enrollment to unblind then why are they doing a spring refresh right before that all-important threshold? Has anyone else asked this simple question? Why not just unblind at 36 months, right? What's the point of a spring refresh? If 36 months past final enrollment doesn't occur until August, then why would they spend money to do a spring refresh so close to this critical date, a date that only became critical when somebody threw it out a couple of months ago as a possible explanation for the company's inaction and total silence? None of it adds up

The company never said that they were waiting for 36 months. However, assuming that is the goal, then it seems logical that they would want to know what the data looks like prior to unblinding. Why would they pick an arbitrary number of months and unblind without knowing if the data was likely to show what they needed for approval?

The people on this board who claim to know so much about the protocols medical trials are supposed to follow in order to attain FDA approval should know that this one doesn't fit the protocols in the least.

You base this on what? Instead of accepting that the people who know what they are talking about actually know what they are talking about you claim without evidence that you know more about their specialty than do they.

But instead they just ignore the evidence in front of their faces and in delusion blame every possible outside factor for this company's failings. I hate to break it to you but management doesn't have any intention of unblinding this trial. Why? Because It is way off the tracks, and it all falls entirely on Good Job Linda.

And finish with more conclusory statements supported by nothing.

You also forgot to mention your contradictory claim that they are giving themselves bonuses . . . in stock that you claim is worthless.

Let me finish with something written by someone who you should be willing to listen to . . .

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136842794

What they wrote in those press releases was accurate, but if everything mentioned in those releases occurred as described, then what it means is that right now there is a lot of work going on behind the scenes to bring this product to market. The best way to ensure that happens successfully and without compromise is to operate in quiet mode. Everything that we have staked our hopes for a better world on, and our hard-earned money on, is now at the end game. That end game involves a very careful, deliberate process of review, analysis, review, analysis, and then more review and analysis until conclusions are drawn and papers are written and published. It takes a lot of time – perhaps many months – and any misstep along the way can jeopardize the whole thing. That's why silence is golden right now. When companies make meaningless statements like "the process is ongoing" just to appease a restless audience, it can do serious damage and end up exacerbating the perceived problem. Do you think anyone on this board would be satisfied with that kind of statement? Ha, not likely. And saying anything more than that could be perceived as manipulation. At this stage of the product trial and review, I can assure you that the SEC will be taking a close look at any public communications this company makes. In my experience, company press releases are often "Exhibit A" of shareholder lawsuits. Sure, they can also do good things – inform shareholders and boost share prices – but even the most innocuous-sounding press release carries an inherent risk of backlash, misinterpretation, and/or just plain dissatisfaction from shareholders. I have seen companies send out seemingly mundane and/or routine press releases and have it come back on them in ways they never imagined. Regardless of intent, PR can be very, very dangerous, and right now dangerous is not what NWBO needs. With so much at stake, it's just not worth the risk to be sending out press releases until there is something final and significant to say. I think they are close, but not quite there yet.